



25 June 2024

Our Ref: RFI 57105

**Freedom of Information Act 2000
Information in Relation to Biologic Medicines in Gastroenterology**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 6 March 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to each of the questions raised has been provided by the Surgery & Elective, Maternity & Paediatric Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Rebecca Manning
Information Governance Officer

Q1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the biologic drugs listed in table 1:

A1. Please see Table 1 for the number of patients treated by the Gastroenterology Department for the listed medications from 01/08/2023 to 31/10/2023*.

Table 1

Treatment	No. of Patients Treated
Adalimumab - Humira	8
Adalimumab Biosimilar	233
Etrasimod	Nil
Filgotinib	16
Golimumab	3
Infliximab - Remicade	4
Infliximab Biosimilar	260
Mirikizumab	Nil
Ozanimod	2
Risankizumab	1
Tofacitinib	4
Upadacitinib	9
Ustekinumab	170
Vedolizumab	121

*Please note, in regards to the figures provided in Table 1 & 2 the Trust can only provide figures up to 31 October 2023 due to migrating to the new Encompass system.

Q2. If you are able to link patient treatment to a disease, could you please provide the number of patients treated in the last 3 months for Ulcerative Colitis ONLY with the biologic drugs listed in table 2:

A2. Please see Table 2 for the number of patients treated for Ulcerative Colitis with the listed medications from 01/08/2023 to 31/10/2023*.

Table 2

Treatment	No. of Patients Treated
Adalimumab - Humira	2
Adalimumab Biosimilar	73
Etrasimod	Nil
Filgotinib	16
Golimumab	3
Infliximab - Remicade	1
Infliximab Biosimilar	99
Mirikizumab	Nil
Ozanimod	2
Risankizumab	Nil
Tofacitinib	4
Upadacitinib	3
Ustekinumab	31
Vedolizumab	78